350 related articles for article (PubMed ID: 34951114)
1. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
Drosten M; Barbacid M
Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
[TBL] [Abstract][Full Text] [Related]
2. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M; Barbacid M
Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
[TBL] [Abstract][Full Text] [Related]
6. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
[No Abstract] [Full Text] [Related]
7. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
8. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
[TBL] [Abstract][Full Text] [Related]
9. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
[TBL] [Abstract][Full Text] [Related]
11. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
12. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
13. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
[TBL] [Abstract][Full Text] [Related]
14. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
15. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
16. Current therapy of KRAS-mutant lung cancer.
Ghimessy A; Radeczky P; Laszlo V; Hegedus B; Renyi-Vamos F; Fillinger J; Klepetko W; Lang C; Dome B; Megyesfalvi Z
Cancer Metastasis Rev; 2020 Dec; 39(4):1159-1177. PubMed ID: 32548736
[TBL] [Abstract][Full Text] [Related]
17. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
[TBL] [Abstract][Full Text] [Related]
18. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
[TBL] [Abstract][Full Text] [Related]
19. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
20. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]